Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. ABIVAX
  6. Summary
    ABVX   FR0012333284

ABIVAX

(ABVX)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Real-time Quote. Real-time Euronext Paris
01/17/2022 01/18/2022 01/19/2022 01/20/2022 01/21/2022 Date
26.6(c) 26.25(c) 26.1(c) 26.1(c) 26.5 Last
7 969 14 718 16 245 15 926 1 785 Volume
+2.31% -1.32% -0.57% 0.00% +1.53% Change
More quotes
Estimated financial data (e)
Sales 2021 33,8 M 38,3 M 38,3 M
Net income 2021 -20,7 M -23,4 M -23,4 M
Net cash position 2021 18,5 M 21,0 M 21,0 M
P/E ratio 2021 -23,0x
Yield 2021 -
Sales 2022 51,8 M 58,6 M 58,6 M
Net income 2022 -14,8 M -16,8 M -16,8 M
Net Debt 2022 14,8 M 16,7 M 16,7 M
P/E ratio 2022 -142x
Yield 2022 -
Capitalization 427 M 484 M 484 M
EV / Sales 2021 12,1x
EV / Sales 2022 8,53x
Nbr of Employees 29
Free-Float 70,0%
More Financials
Company
ABIVAX mobilizes the body's natural immune machinery to treat patients with inflammatory diseases, viral infections and cancers. As a clinical phase company, ABIVAX is leveraging its antiviral and immune platforms to develop drug candidates leading to a cure for ulcerative colitis, Crohn's disease, and rheumatoid arthritis (ABX464), and liver cancer (ABX196). The Company's mission is to use its drug development... 
More about the company
Ratings of ABIVAX
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about ABIVAX
04:19aAbivax phase 1/2 clinical study results of ABX196 in liver cancer to be presented on Ja..
AQ
01/19Abivax's phase 1/2 clinical study results of ABX196 in liver cancer to be presented on ..
EQ
01/19Abivax SA Announces the Detailed Results of the Dose Escalation Phase of Its Clinical P..
CI
01/13Abivax Gets EU Support To Advance Ulcerative Colitis Drug Into Late-Stage Trial
MT
01/13Abivax's Ulcerative Colitis Drug Gets EU Agency Support to Proceed to Late-Stage Testin..
MT
01/13Abivax receives EMA Scientific Advice supportive of moving ABX464 into phase 3 clinical..
EQ
2021Abivax to present at the J.P. Morgan 40th Annual Healthcare Conference
AQ
2021Abivax to present at the J.P. Morgan 40th Annual Healthcare Conference
EQ
2021GLOBAL MARKETS LIVE : Hermès, Walt Disney, Apple, Novartis, Square...
2021Abivax receives FDA feedback with guidance on advancing ABX464 into phase 3 clinical te..
AQ
2021Abivax's phase 1/2 clinical study results of ABX196 in liver cancer show good tolerabil..
AQ
2021Abivax Gets US FDA Feedback, Guidance On Late-Stage Trial For Ulcerative Colitis Therap..
MT
2021Abivax receives FDA feedback with guidance on advancing ABX464 into phase 3 clinical te..
EQ
2021Abivax SA Receives FDA Feedback with Guidance on Advancing ABX464 into Phase 3 Clinical..
CI
2021Abivax's Liver Cancer Combo Shows Signs Of Clinical Benefit In Early-Stage Study
MT
More news
News in other languages on ABIVAX
01/19ABIVAX : Bilan semestriel du contrat de liquidité au 31 décembre 2021.
01/19Un mariage et quatre enterrements
01/19Les valeurs à suivre aujourd'hui à la Bourse de Paris Mercredi 19 janvier 2022
01/19ABIVAX : les résultats de la phase 1/2 d’ABX196 dans le cancer du foie présentés à l'ASCO ..
01/19EN DIRECT DES MARCHES : Orange, Gecina, Eurazeo, ASML, Richemont, Sony, Ford, EQT, Burberr..
More news
Chart ABIVAX
Duration : Period :
ABIVAX Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ABIVAX
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 26,10 €
Average target price 62,96 €
Spread / Average Target 141%
EPS Revisions
Managers and Directors
Hartmut J. Ehrlich Chief Executive Officer
Didier Blondel Chief Financial Officer & Secretary
Philippe Pouletty Chairman
Didier Scherrer Vice President-Research & Development
Paul Gineste Vice President-Clinical Operations
Sector and Competitors
1st jan.Capi. (M$)
ABIVAX-8.58%484
MODERNA, INC.-34.04%67 921
LONZA GROUP AG-13.71%53 315
IQVIA HOLDINGS INC.-13.38%46 690
SEAGEN INC.-13.93%24 331
ICON PUBLIC LIMITED COMPANY-17.37%20 831